Challenges in managing CDI include the emergence of hypervirulent strains, such as the NAP1/BI/027 strain, which are associated with more severe disease and higher recurrence rates. Additionally, the persistence of spores in the environment and the potential for asymptomatic carriage complicate efforts to control transmission. Ongoing research into vaccines and novel therapeutics is crucial to address these challenges.
